Swiss Administrative Court Mandates Transparency for Pandemic Vaccine Contracts

The Swiss Federal Administrative Court has ruled that the government must disclose its procurement contracts with pharmaceutical firms for COVID 19 vaccines.

By: AXL Media

Published: Feb 17, 2026, 2:15 PM EST

Source: SWI swissinfo.ch

he Swiss Federal Administrative Court has officially upheld the appeals of three private citizens, ordering the federal government to grant access to contracts concluded with pharmaceutical providers. Since the height of the pandemic, the Federal Office of Public Health (FOPH) has maintained strict confidentiality over the specific terms of these deals, citing business secrecy and sensitive negotiations. However, the court's recent intervention signals a significant shift toward public accountability, requiring that the financial and logistical frameworks of these multi billion franc agreements be made accessible to the public.

This legal development represents a major victory for the principle of freedom of information in Switzerland. The court determined that the public interest in understanding how tax revenue was allocated during the global health crisis outweighs the commercial confidentiality claims made by the pharmaceutical industry. By forcing the disclosure of these documents, the judiciary is addressing long standing concerns about the lack of oversight in emergency procurement. This ruling establishes a critical precedent for future government interactions with private contractors during national emergencies, emphasizing that transparency is a fundamental component of public trust.

The demand for transparency is closely linked to the massive financial waste associated with Switzerland's vaccine strategy. Reports from the Federal Finance Administration indicate that the country purchased medical supplies worth approximately CHF 2.3 billion between 2020 and 2023. However, only about a quarter of the purchased doses were eventually administered to the population. Consequently, Switzerland was forced to dispose of expired vaccines valued at over CHF 1.3 billion. The newly mandated contract disclosures are expected to reveal whether the procurement terms included flexible delivery options that could have mitigated this significant loss of public funds.

The ruling directly impacts the relationship between the Swiss state and major global pharmaceutical firms. While the names of specific companies were often redacted in previous discussions, the disclosure is expected to shed light on the bargaining power held by these corporations during the pandemic. Critics have argued that the initial contracts were heavily skewed in favor of the producers, shiel...